PTPN9 dephosphorylates IGF1RY1165/1166 and alleviates IGF1R-mediated resistance to tyrosine kinase inhibitor in cholangiocarcinoma

Abstract Cholangiocarcinoma (CCA) is an aggressive malignancy with limited therapeutic options. Increasing evidence suggests that a subset of CCA patients can benefit from multiple tyrosine kinase inhibitors (mTKIs) such as surufatinib. Biomarker studies that can identify potential responders to mTK...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Jia-ming Hu, Hui-qiang Liu, Ming-hui Zhang, Tian-li Chen, An-da Shi, Qiang Gao, Yun-jia Liu, Xin Wang, Kai-yang Sun, Jian Deng, Yun-fei Xu, Chang Pan, Kang-shuai Li, Zong-li Zhang
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2025-11-01
Цуврал:	Journal of Experimental & Clinical Cancer Research
Нөхцлүүд:	Cholangiocarcinoma Surufatinib IGF1R PTPN9 CAF
Онлайн хандалт:	https://doi.org/10.1186/s13046-025-03594-2
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!